Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 août 2019 09h24 HE | Source: OPKO Health, Inc.

OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

MIAMI, Aug. 29, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the last patient has completed the final visit in the Company’s pivotal Phase 3 study evaluating the...
07 août 2019 16h05 HE | Source: OPKO Health, Inc.

OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results

MIAMI, Aug. 07, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30, 2019. Business Highlights RAYALDEE...
01 août 2019 08h00 HE | Source: OPKO Health, Inc.

OPKO Health to Report Second Quarter 2019 Financial Results on August 7, 2019

MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended June 30, 2019, as well as provide guidance on...
01 juil. 2019 09h29 HE | Source: OPKO Health, Inc.

OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers

SOMOS, New York City’s Largest Multi-Cultural Physician-Led Network, Selects BioReference as Preferred Provider for Diagnostic Testing BioReference to also assist with Patient-Centered Data...
28 juin 2019 08h00 HE | Source: OPKO Health, Inc.

Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test

MIAMI, June 28, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination (LCD) for the 4Kscore®...
20 juin 2019 08h00 HE | Source: OPKO Health, Inc.

OPKO Health Submits De Novo Request to the U.S. FDA for the 4Kscore® Test

MIAMI, June 20, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that the Company has submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory...
07 mai 2019 16h20 HE | Source: OPKO Health, Inc.

OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results

MIAMI, May 07, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2019. Business Highlights RAYALDEE...
30 avr. 2019 08h00 HE | Source: OPKO Health, Inc.

OPKO Health to Report First Quarter 2019 Financial Results on May 7, 2019

MIAMI, April 30, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended March 31, 2019, as well as provide guidance...
12 avr. 2019 08h00 HE | Source: OPKO Health, Inc.

OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial

MIAMI, April 12, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today reported additional results from the per protocol patient population from the Phase 2 dose escalation trial of...
21 mars 2019 08h00 HE | Source: OPKO Health, Inc.

OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial

MIAMI, March 21, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced positive topline results from a Phase 2 dose escalation trial of OPK88003 to treat type 2 diabetes and...

Page précédente